Skip to Main Content

Paper Details

Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
Nat Cancer
137
2021
B cells, CD138+, CD138+ plasma cells, Cabozantinib, HCC, HCCs, Locally Advanced HCC, Nivolumab, T effector cells, cabozantinib, hepatocellular carcinoma, patients
Author NameAffiliation
Ludmila DanilovaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Ludmila DanilovaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Genevieve L Stein-O'BrienMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine
Genevieve L Stein-O'BrienSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Elana J FertigMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine
Elana J FertigSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Elana J FertigJohns Hopkins University School of Medicine
Elana J FertigJohns Hopkins University Whiting School of Engineering
Elizabeth M JaffeeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • 1 - 9

Datasets

Release 1.2